Navigation Links
Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours
Date:12/6/2012

HOLLYWOOD, Fla. and EVANSTON, Ill., Dec. 6, 2012 /PRNewswire/ -- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported positive results from a Phase IIa clinical trial of its lead antidepressant compound, GLYX-13.  GLYX-13 is a novel partial agonist of the NMDA receptor.  The Phase Ila results are being presented this week at the 51st Annual Meeting of the American College of Neuropsychopharmacology (ACNP).

The Phase IIa results show that a single administration of GLYX-13 produced statistically significant reductions in depression scores in subjects who had failed treatment with one or more antidepressant agents.  The reductions were evident within 24 hours and persisted for an average of seven days.  Importantly, the effect size, a measure of the magnitude of the drug's antidepressant efficacy, observed at 24 hours and at seven days after a single administration of GLYX-13, was nearly double the effect size seen with most other antidepressant drugs after 4-6 weeks of repeated dosing.

In the Phase IIa trial, GLYX-13 was well tolerated.  Reported side effects were mild to moderate and were consistent with those observed in subjects receiving placebo.  Consistent with previous studies, GLYX-13 did not produce any of the schizophrenia-like psychotomimetic effects associated with other drugs that modulate the NMDA receptor.

"These data are an important step in validating Naurex's mission of developing breakthrough therapies for depression and other CNS disorders," said Derek Small, CEO of Naurex.  "Our founder discovered a new class of drugs that appeared to have the remarkable antidepressant efficacy of ketamine-like compounds, but without their limiting side effects.  These Phase II results suggest that this discovery may translate into measurable health improvements for individuals with depression, which
'/>"/>

SOURCE Naurex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Topokine Announces Dosing of First Subject in a Phase I Clinical Trial of XAF5 Gel for Local Reduction of Subcutaneous Fat
2. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
3. Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
4. AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation
5. NIH Awards New England Biolabs a Phase II SBIR Grant for the Research and Development of Novel Enzymes for Epigenetic Studies
6. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
7. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
8. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
9. A Phase IIa Interferon Free Combination Hepatitis C Trial of Simeprevir (TMC435) and TMC647055 Will Commence Shortly
10. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
11. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval ... for the use of Medtronic,s SynchroMed ® II ... for use with United Therapeutics, Remodulin ® (treprostinil) ...
(Date:12/24/2014)... 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... clinical grade hypothermic storage and cryopreservation freeze ... cells and tissues  ("BioLife" or the "Company"), today announced that ... May 4, 2015 (the "Annual Meeting"). Because the ...
(Date:12/24/2014)... Earlier this year in a June 24 international ... Stem Cell Technology Center, LLC ( ASCTC ) focused attention ... adult tissue stem cells. His title “Asymmetric Self-Renewal by ... Future,” embodied the essence of his message to congress participants. ...
(Date:12/24/2014)... Island, New York (PRWEB) December 23, 2014 ... and the Long Island Affiliate of ITRA Global, the national ... slow but steady recovery. This is evidenced by the ... the strong stock market. Low energy costs have held ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... dedicated to connecting buyers and sellers of technology businesses through ... provides targeted access to buyers and sellers of technology business, ... ... Atlanta, GA (PRWEB) November 18, 2008 -- TechMandA.com ...
... is leveraging its extensive experience in multi-GPU ... media creation to provide scientists, engineers and ... The BOXX Personal Supercomputer (PSC), which will ... during this week,s SC08 Conference, the top ...
... Two-thirds of all port wine stain birthmarks occur on the face. ... that safely fades these reddish-purple skin lesions that can have a huge ... study evaluating the combined use of pulsed dye laser (PDL) therapy and ... , ...
Cached Biology Technology:TechMandA.com Marketplace Streamlines M&A Process for Technology Businesses 2TechMandA.com Marketplace Streamlines M&A Process for Technology Businesses 3BOXX Personal Supercomputer for Research Scientists Featured at SC08 2Pilot Study Finds Adding Topical Imiquimod To Laser Therapy Improves The Response Of Port Wine Stain Birthmarks 2Pilot Study Finds Adding Topical Imiquimod To Laser Therapy Improves The Response Of Port Wine Stain Birthmarks 3Pilot Study Finds Adding Topical Imiquimod To Laser Therapy Improves The Response Of Port Wine Stain Birthmarks 4
(Date:12/17/2014)... fundamentally transforming the travel experience and nowhere is this ... decade, ePassports, biometric readers, and secure document scanners have ... via eGates and Automated Passport Control (APC) Kiosks at ... across the globe. According to ...
(Date:12/11/2014)... 2014 Research and Markets , ... has announced the addition of the "Biometrics Market ... One major trend emerging in this market ... systems utilize more than one characteristic of an individual ...
(Date:12/10/2014)... been here before: you desperately need to sign into your online ... answer to your secret question. What,s your dog,s birthday? Who was ... , a digital infrastructure security company, launches the app ... with usernames, passwords and PINs – 1U TM . ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... determining the potential effects pesticides could pose to ... Agency, National Marine Fisheries Service (NMFS), and Fish ... scientific approach, says a new report from the ... use a risk assessment approach that addresses problem ...
... Institute of Environmental Science and Technology at the Universitat ... Political Ecology over the next three years, within the ... to create an international network of expertise in the ... studies that takes into account the multidisciplinary training needed ...
... a recent lottery winner having been exhumed for foul play ... can do to avoid the same fate. A new report ... suggests that riboflavin, also known as vitamin B2, may mitigate ... report shows that zebrafish are a viable model for investigating ...
Cached Biology News:Agencies should use common approach to evaluate risks pesticides pose to endangered species 2Agencies should use common approach to evaluate risks pesticides pose to endangered species 3European support for the first network of research and training in political ecology 2European support for the first network of research and training in political ecology 3Zebrafish study suggests that vitamin B2 (riboflavin) is an antidote to cyanide poisoning 2
Request Info...
Unique enzyme blend containing Taq and Pwo DNA Polymerase and another thermostable enzyme. The Expand 20 kbPLUS PCR System also includes an optimized reaction buffer, MgCl2 solution, and a human cont...
... EC105 power supply is a highly compact, extremely ... single adjustment knob and one hi-lo range switch ... volt increments from 20 to 250 volts. One ... indicating output voltage to output current. For maximum ...
...
Biology Products: